DURAMORPH PF
Clinical safety rating
cautionComprehensive clinical and safety monograph for DURAMORPH PF (DURAMORPH PF).
Morphine is a full opioid agonist that primarily acts on mu-opioid receptors in the central nervous system to produce analgesia, euphoria, and sedation. It also interacts with kappa and delta receptors. It inhibits ascending pain pathways and alters pain perception and response.
| Metabolism | Primarily hepatic via glucuronidation by UGT2B7 to morphine-3-glucuronide (M3G, inactive) and morphine-6-glucuronide (M6G, active); minor metabolism via CYP2D6 to normorphine. |
| Excretion | Primarily renal (approximately 90% as morphine-3-glucuronide and morphine-6-glucuronide, with 10% as unchanged morphine). Biliary/fecal excretion accounts for less than 10%. |
| Half-life | Terminal elimination half-life of morphine is approximately 2-4 hours in adults. In neonates and elderly, half-life may be prolonged (up to 4.5-6.5 hours). Context: half-life may be extended in renal impairment due to accumulation of active metabolites. |
| Protein binding | 30-35% bound to albumin. |
| Volume of Distribution | 3-5 L/kg (range 1-6 L/kg). Clinical meaning: indicates extensive tissue distribution. |
| Bioavailability | Epidural/Intrathecal: effectively 100% at site of action (systemic bioavailability from epidural absorption is ~30-40% due to first-pass metabolism). Oral: 20-40% (not relevant for DURAMORPH PF). |
| Onset of Action | Epidural: 15-30 minutes; Intrathecal: 15-30 minutes (may be slower with higher doses). |
| Duration of Action | Epidural: 12-24 hours (dose-related); Intrathecal: 12-24 hours (dose-related). Note: duration is longer than systemic administration due to local effect. |
| Molecular Weight | 285.34 |
0.8 to 10 mg via epidural injection as a single dose or via continuous epidural infusion at 0.1 to 1 mg/hour. For intrathecal use: 0.2 to 1 mg as a single dose. Intravenous: 2 to 10 mg for analgesia every 2-4 hours as needed.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 50-90 mL/min: no adjustment; GFR 10-50 mL/min: reduce dose by 25-50% and extend dosing interval; GFR <10 mL/min: avoid use or reduce dose by 50% and administer every 6-8 hours with close monitoring. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 25-50% and monitor; Child-Pugh Class C: avoid use or reduce dose by 50% and extend dosing interval. |
| Pediatric use | Epidural: 0.03 to 0.05 mg/kg as a single dose, may repeat every 4-6 hours; continuous infusion: 0.002 to 0.008 mg/kg/hour. Intrathecal: 0.01 to 0.02 mg/kg as a single dose. Intravenous: 0.05 to 0.1 mg/kg every 2-4 hours prn. |
| Geriatric use | Reduce initial dose by 25-50% and titrate cautiously due to increased sensitivity and risk of respiratory depression. Use non-PVC tubing and avoid in renal impairment. |
| 1st trimester | Morphine is not recommended in the first trimester due to potential teratogenic effects observed in some animal studies, though human data are limited. Use only if clearly needed. |
| 2nd trimester | May cause fetal dependence and neonatal withdrawal syndrome with chronic use. Use lowest effective dose for shortest duration. |
| 3rd trimester | Associated with neonatal respiratory depression, withdrawal, and potential premature labor. Avoid prolonged use near term. |
Clinical note
Comprehensive clinical and safety monograph for DURAMORPH PF (DURAMORPH PF).
| Placental transfer | Morphine crosses the placenta readily, with fetal plasma concentrations reaching 60-100% of maternal levels. Transfer occurs via passive diffusion and may be enhanced by placental transporters. |
| Breastfeeding | Morphine enters breast milk in small amounts. With maternal use, monitor infant for drowsiness, respiratory depression, and withdrawal symptoms. Avoid breastfeeding if mother is on high doses or has impaired drug metabolism. Use alternative analgesics if possible. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Preservative-free morphine (Duramorph PF) is FDA Pregnancy Category C. First trimester: Limited human data; animal studies show increased risk of neural tube defects and skeletal anomalies at high doses. Second and third trimesters: Chronic use may cause fetal opioid dependence and neonatal opioid withdrawal syndrome (NOWS) after delivery. Not associated with major congenital malformations in human studies, but risk-benefit must be assessed. |
| Fetal Monitoring | Continuous maternal monitoring for respiratory rate, oxygen saturation, sedation level, and pain scores. Fetal monitoring: Non-stress test and biophysical profile in third trimester for chronic use. During labor, fetal heart rate monitoring is essential. For neonates, monitor for signs of withdrawal (NOWS) for at least 48 hours after delivery if mother used chronically. |
| Fertility Effects | Chronic opioid use may cause menstrual irregularities (e.g., anovulation, amenorrhea) due to suppression of gonadotropin-releasing hormone (GnRH). Reversible upon cessation. No known direct effect on spermatogenesis, but sexual dysfunction (e.g., erectile dysfunction, libido changes) may occur in both sexes. Data on fertility impact are limited. |
■ FDA Black Box Warning
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; NEONATAL OPIOID WITHDRAWAL SYNDROID; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS. Ensure proper patient selection, monitoring, and dispensing.
| Serious Effects |
Hypersensitivity to morphine or any componentAcute or severe bronchial asthmaUpper airway obstructionRespiratory depression (in absence of resuscitative equipment)Suspected paralytic ileusConcurrent use of MAO inhibitors or within 14 daysSevere hepatic impairment
| Precautions | Risk of respiratory depression, especially in elderly, cachectic, or debilitated patients; central nervous system depression; serotonin syndrome with serotonergic drugs; adrenal insufficiency; hypotension; seizures; severe hypotension; use in patients with head injury; use in patients with biliary tract disease; use in patients with pancreatic disease; use in patients with renal impairment; use in patients with hepatic impairment; use in patients with respiratory conditions; use in patients with gastrointestinal obstruction; use in patients with prostatic hyperplasia; use in patients with urinary retention; use in patients with hypothyroidism; use in patients with adrenocortical insufficiency; use in patients with toxic psychosis; use in patients with alcoholism; use in patients with delirium tremens; use in patients with kyphoscoliosis; use in patients with severe obesity; use in patients with sleep apnea; use in patients with myxedema; use in patients with chronic obstructive pulmonary disease; use in patients with cor pulmonale; use in patients with respiratory depression; use in patients with acute or severe bronchial asthma; use in patients with paralytic ileus; use in patients with hypersensitivity to morphine; use in patients with gastrointestinal obstruction; weaning from opioids; physical dependence; withdrawal; tolerance; impaired mental or physical abilities; driving; operating machinery; risk of overdose; accidental ingestion; neonatal opioid withdrawal syndrome; concomitant use with alcohol; concomitant use with benzodiazepines; concomitant use with CNS depressants; abuse potential; monitoring; pregnancy; lactation; renal impairment; hepatic impairment; elderly; pediatric; recent intracranial surgery; increased intracranial pressure; impaired consciousness; coma; convulsive disorders; hypotension; hypovolemia; severe pulmonary disease; respiratory depression; sleep-related breathing disorders; drug dependence; misuse; addiction; abuse; diversion; storage and disposal. |
| Food/Dietary | Avoid alcohol and grapefruit juice for at least 24 hours after administration. Alcohol potentiates CNS depression and respiratory effects. No specific food restrictions beyond standard postoperative diet; however, patients should avoid large meals if nauseated. Maintain adequate fluid and fiber intake to mitigate constipation. |
| Clinical Pearls | DURAMORPH PF is a preservative-free morphine sulfate solution indicated for epidural or intrathecal administration. Onset of analgesia occurs within 10-15 minutes after epidural injection and peaks at 30-60 minutes; intrathecal onset is faster (5-10 minutes) with duration up to 24 hours. Due to risk of delayed respiratory depression, patients must be monitored in a setting equipped for resuscitation for at least 24 hours after administration. Naloxone should be readily available. Do not use if solution is discolored or contains precipitate. Avoid concurrent use with MAOIs or within 14 days of discontinuation. |
| Patient Advice | This medication is given directly into the spine to control severe pain. You will be closely monitored in the hospital. Report any trouble breathing, severe drowsiness, or itching. · Do not drive or operate machinery for at least 24 hours after administration. Avoid alcohol and sedatives, which may increase respiratory depression. · You may experience nausea, vomiting, constipation, or urinary retention. Notify your healthcare provider if these become severe. · If you have a history of opioid addiction, head injury, asthma, or kidney/liver disease, inform your doctor before treatment. · Do not breastfeed for 24 hours after receiving this medication. Inform all healthcare providers that you have received an intrathecal opioid. |
Loading safety data…